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Quality-adjusted life-years (QALYs) and life-years (LYs) were used as the summary benefit measure. An annual discount rate of 3% was applied.
Cost data:
The health services included in the analysis were the costs of nurse case management, visits to specialists, participation in group classes, administrative overheads (including visit scheduling, coordination of care with the primary care physician, management of referrals, and support of the database registry), pharmaceuticals and supplies, hospital and emergency room expenditures, and diabetes-specific costs of complications. The data on costs and resource consumption were derived from published studies and the experience of Project Dulce. All costs were in US dollars ($). Future costs were discounted at an annual rate of 3% and the price year was 2003.
Analysis of uncertainty:
A deterministic sensitivity analysis was undertaken by varying key clinical and economic inputs, the time horizon, and the discount rate. Cost-effectiveness acceptability curves were calculated using a non-parametric bootstrapping approach.
Results
In the uninsured cohort, Project Dulce led to an improvement of 1.1 LYs and 0.9 QALYs, and additional costs of $8,991, resulting in incremental costs of $7,933 per LY gained and $10,141 per QALY gained.
In the CMS cohort, Project Dulce led to an improvement of 0.6 LYs and 0.4 QALYs, and additional costs of $10,921, resulting in incremental costs of $18,976 per LY gained and $24,584 per QALY gained.
In the Medi-Cal cohort, Project Dulce led to an improvement of 0.3 LYs and 0.3 QALYs, and additional costs of $11,792, resulting in incremental costs of $36,056 per LY gained and $44,941 per QALY gained.
In the commercial cohort, Project Dulce led to an improvement of 0.2 LYs and 0.2 QALYs, and additional costs of $12,368, resulting in incremental costs of $57,587 per LY gained and $69,587 per QALY gained.
The cost-effectiveness acceptability curve showed that, at a willingness to pay of $50,000 per QALY gained, Project Dulce had a 100% probability of being cost-effective in the uninsured cohort, a 92% probability in the CMS cohort, a 57% probability in the Medi-Cal cohort, and a 31% probability in the commercial cohort. The deterministic sensitivity analysis suggested that reducing the A1c treatment effect by 50% substantially reduced the cost-effectiveness of the intervention in all groups. Variations in other model inputs did not substantially alter the base-case findings, which always remained below a threshold of $100,000 per QALY.
